Journalclub

Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years
Beth Han et al.
JAMA Psychiatry. doi:10.1001/jamapsychiatry.2025.0054 

Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism:
A randomized clinical trial
Peijun Tian et al.
Brain, Behavior, and Immunity 100 (2022) 233–241

Pregabalin use in forensic hospitals and prisons in German speaking countries – a survey study of physicians
Michal Novotny et al.
Frontiers in Public Health DOI 10.3389/fpubh.2023.1309654

Antipsychotic continuation during pregnancy and risk of postpartum relapse in women with schizophrenia: nationwide register-based study
Sunghyuk Kang et al.
The British Journal of Psychiatry (2025)
https://doi.org/10.1192/bjp.2024.247 

The effectiveness and safety of dialectical behavior therapy for suicidal ideation and behavior in autistic adults: a pragmatic randomized controlled trial
Anne Huntjens et al.
https://doi.org/10.1017/S0033291724000825 Published online by Cambridge University Press

Continuous Dopamine D2 Receptor Blockade and Long-Term Outcome in First-Episode Schizophrenia
Jari Tiihonen et al.
Am J Psychiatry 182:4, April 2025

Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients
With Schizophrenia
Heidi Taipale et al.
Am J Psychiatry 180:5, May 2023

Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
A Randomized Clinical Trial
Christian S. Hendershot et al.
JAMA Psychiatry. 2025;82(4):395-405. doi:10.1001/jamapsychiatry.2024.4789

Comparison of Acute Followed by Maintenance ECT vs Clozapine on Psychopathology and Regional Cerebral Blood Flow in Treatment-Resistant Schizophrenia: A Randomized Controlled Trial
Biswa Ranjan Mishra et al.
Schizophrenia Bulletin vol. 48 no. 4 pp. 814–825, 2022
https://doi.org/10.1093/schbul/sbac027

Housing situation and healthcare for patients in a psychiatric centre in Berlin, Housing situation and healthcare for patients in a psychiatric centre in Berlin, Germany: a cross-sectional patient survey
Stefanie Schreiter et al.
BMJ Open 2019;9:e032576. doi:10.1136/bmjopen-2019-03257

Antidepressant use and cognitive decline in patients with dementia: a national cohort study
Minjia Mo et al.
BMC Medicine, (2025) 23:82
https://doi.org/10.1186/s12916-03851-3

Trauma-focused therapy in early psychosis: results of a feasibility randomized controlled trial of EMDR for psychosis (EMDRp) in early intervention settings
Filippo Varese et al.
Cambridge University Press
https://doi.org/10.1017/S0033291723002532 

A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial
Nele Assmann et al.
Lancet Psychiatry 2025; 12: 366–76

Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK
Anthony J Cleare et al.
Lancet Psychiatry 2025; 12: 276–88

Sommerferien, Start ab dem 11.08.2025

Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression
Antonio Del Casale et al
JAMA Psychiatry. 2025;82(8):810-817. doi:10.1001/jamapsychiatry.2025.0200

Early Access to Testosterone Therapy in Transgender and Gender-Diverse Adults Seeking Masculinization
A Randomized Clinical Trial
Brendan J. Nolan et al.
JAMA Network Open. 2023;6(9):e2331919.doi:10.1001/jamanetworkopen.2023.31919 

Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression:
a placebo controlled, double-blind, randomised trial in the UK
Michael Browning  et al.
Lancet Psychiatry 2025; 12: 579–89

Winterferien, Start ab dem 06.01.2026